Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

acridine carboxamide

A tricyclic acridine-based (or carboxamide-based) drug with dual topoisomerase inhibitor and potential antineoplastic activities. Acridine carboxamide inhibits both topoisomerases I and II and intercalates into DNA, resulting in DNA damage, the disruption of DNA repair and replication, the inhibition of RNA and protein synthesis, and cell death.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Abbreviation:	DACA
Code name:	SN 22995 XR5000
Chemical structure:	N-(2-(dimehtylamino)ethyl)acridine-4-carboxamide N-(2-(dimethylamino)ethyl)acridine-4-carboxamide

acridine carboxamide

Search NCI's Drug Dictionary